Skip to main content
PCVX logo

PCVX · Vaxcyte, Inc. · Financials

Track PCVX — free
$60.16 +1.64 (+2.80%) Play latest call Q4 2025 earnings call transcript
Market Cap
$9.26B
Shares
158.30M
Volume · Nov 19 172.87K Avg daily vol (3M) 2.16M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Net Income
-$766.63M -65.2%
FY2025 Net Income FY2018–FY2025
Diluted EPS
-$5.63 -48.2%
FY2025 Diluted EPS FY2020–FY2025
Operating Cash Flow
-$655.58M -44.8%
FY2025 Operating Cash Flow FY2018–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
$1.09B $794.31M $476.64M $332.34M $169.45M $78.41M $73.56M $45.61M $30.15M
$138.17M $129.37M $92.9M $60.7M $39.81M $25.26M $16.02M $8.55M $5.39M
— $16.4M $7M $3.2M $2.83M $1.8M $1.41M $1.23M $1.04M
$1.23B $923.68M $569.55M $468.04M $232.26M $103.67M $89.58M $54.15M $35.53M
-$1.23B -$923.68M -$569.55M -$468.04M -$232.26M -$103.67M -$89.58M -$54.15M -$35.53M
— — $0 $0 $2000 $7000 $7000 $40K $75K
$102.01M $119.72M $109.99M $62.91M $8.36M $344K $244K $632K $903K
$82.69M $157.05M $105.62M $65.78M $8.77M $3.59M $364K $3.88M $6.05M
$0 $0 $0 $0 — — — — —
-$1.15B -$766.63M -$463.93M -$402.27M -$223.49M -$100.08M -$89.22M -$50.27M -$29.49M
-$1.16B -$761.17M -$467.98M -$401.73M -$223.61M -$100.32M -$89.22M -$50.27M —
USD/shares -$8.07 -$5.63 -$3.80 -$4.14 -$3.44 -$1.93 -$3.02 — —
USD/shares -$8.07 -$5.63 -$3.80 -$4.14 -$3.44 -$1.93 -$3.02 — —
shares — 136.09M 122M 97.16M 64.88M 51.92M 29.55M 3.8M 3.63M
shares — 136.09M 122M 97.16M 64.88M 51.92M 29.55M 3.8M 3.63M
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Read debt and covenant terms in your AI or your code through MCP and the API →

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Finance lease liabilities 2026-09-30 USD 107,778,000 10-Q filed 2026-11-04
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current finance lease liabilities
USD 10,922,000
Noncurrent finance lease liabilities
USD 96,856,000
Operating lease liabilities 2026-09-30 USD 114,057,000 10-Q filed 2026-11-04
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current operating lease liabilities
USD 6,692,000
Noncurrent operating lease liabilities
USD 107,365,000
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
—
Peer median 9.35×
EV/EBIT
—
Peer median 45.63×
P/E (TTM)
—
Peer median 43.86×
Price/Sales (TTM)
—
Peer median 12.60×
Price/Book
3.72×
Peer median 4.95×

Peer medians compare against the 141 similar-size Biotechnology companies (of 593 listed).

Valuation over time computed as of each quarter's filing date

Key facts CIK 1649094 CUSIP 92243G108 13F (30d) 372 filings 338 filers Visit website Investor relations